“…Unfortunately, among oncologists often still stands the opinion that in the elderly dose intensity may mean heavy toxicity rather than efficacy, a belief frequently leading to unjustified chemotherapy undertreatment. Undoubtedly, due to comorbidities, polypharmacy and compromised organ function, this population is a challenging one but an accurate pre-treatment assessment and the use of patient-adapted regimens can favor the achievement of a good clinical response with low morbidity and mortality [17,19,20]. According to our data, baseline hemoglobin and BMI significantly impact on delivered RDI; as also suggested by the literature, nutritional deficit as well as even mild anemia must be promptly managed in elderly patients candidates to chemotherapy [21,22].…”